A simple AI-driven process intensification protocol for active pharmaceutical ingredients synthesis
Autor/a
Otros/as autores/as
Fecha de publicación
2025-11ISSN
2666-8211
Resumen
The synthesis of active pharmaceutical ingredients (APIs) traditionally relies on batch reactors, which often exhibit challenges in terms of both selectivity and heat transfer control. This study investigated the Aza-Michael addition between methylamine and 2-vinylpyridine to synthetize betahistine, an analogue of histamine, converting a traditional batch process into a continuous flow reaction. The aim of the study was to define an intensification protocol capable of identifying optimized operating conditions to maximise betahistine production. A dedicated experimental setup was developed using a custom-built PTFE-based tubular microreactor which allowed for an optimal control of pressure, temperature, residence time, and reactants molar ratio. Analytical characterization was performed using both UHPLC and H-NMR. Process intensification was achieved using two different approaches: a traditional one, based on deterministic mathematical models to simulate the chemical reactions involved, and a modern approach based on Feedforward Neural Networks. The highest selectivity experimentally observed was approximately 82% at a 2:1 methylamine to 2-vinylpyridine ratio and 150°C, with a residence time of 4 minutes. Both optimizing approaches lead to the same results, confirming the advantages of using suitable intensification protocols for shifting to continuous flow batch processes, especially in pharmaceutical synthesis.
Tipo de documento
Artículo
Versión del documento
Versión publicada
Lengua
Inglés
Materias (CDU)
54 - Química
Palabras clave
Páginas
p.17
Publicado por
Elsevier
Publicado en
Chemical Engineering Journal Advances 2025, 24
Citación recomendada
Esta citación se ha generado automáticamente.
Este ítem aparece en la(s) siguiente(s) colección(ones)
Derechos
© L'autor/a
Excepto si se señala otra cosa, la licencia del ítem se describe como http://creativecommons.org/licenses/by-nc-nd/4.0/


